Prediction of Early Relapse After Pimozide Discontinuation by Response to D-amphetamine During Pimozide Treatment
Overview
Authors
Affiliations
Thirteen schizophrenic patients underwent a d-amphetamine infusion while being treated with pimozide, an antipsychotic agent and a relatively specific dopamine (DA) blocker. Six patients who showed an acute increase in psychosis with d-amphetamine relapsed within 3 months after pimozide withdrawal. Of the seven patients who did not change in psychosis with d-amphetamine, six did not relapse after pimozide discontinuation (Fisher's exact test, p less than 0.005). Retrospectively, the psychosis-inducing effects of d-amphetamine were found to be predictive of psychotic exacerbation following subsequent pimozide withdrawal. Pimozide failed to block the psychotogenic effects of d-amphetamine in six patients indicating that other mechanisms besides DA may play a role in psychotic decompensation. The d-amphetamine infusion paradigm should be studied further to determine its clinical value for identifying which schizophrenic patients are at risk for relapse after discontinuation of neuroleptic treatment.
New Concepts in Dopamine D Receptor Biased Signaling and Implications for Schizophrenia Therapy.
Urs N, Peterson S, Caron M Biol Psychiatry. 2016; 81(1):78-85.
PMID: 27832841 PMC: 5702557. DOI: 10.1016/j.biopsych.2016.10.011.
Clinton S, Sucharski I, FINLAY J Psychopharmacology (Berl). 2005; 183(4):404-12.
PMID: 16307295 DOI: 10.1007/s00213-005-0221-2.
Weiner I Psychopharmacology (Berl). 2003; 169(3-4):257-97.
PMID: 12601500 DOI: 10.1007/s00213-002-1313-x.
Myths and mystifications of managed care.
Docherty J J Ment Health Adm. 1990; 17(2):138-44.
PMID: 10107491 DOI: 10.1007/BF02521142.
VAN KAMMEN D, Docherty J, Marder S, Rosenblatt J, Bunney Jr W Psychopharmacology (Berl). 1985; 87(1):111-5.
PMID: 3933028 DOI: 10.1007/BF00431789.